title: Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies.
abstract: OBJECTIVE
  The development of reduced-intensity conditioning regimens rather than myeloablative regimens for allogeneic stem cell transplantation has led to decreased treatment-related mortality and increased use of this treatment modality, especially in older patients with hematological malignancies. No randomized controlled trials have been performed resulting in determining effectiveness on phase II studies, which rarely report on long-term survival.
  
  
  METHODS
  In an attempt to address this limitation, we analyzed a single-center cohort of 100 consecutive patients with hematological malignancies undergoing allogeneic stem cell transplantation from a human leukocyte antigen-matched related donor with median follow-up of 60 months. The reduced-intensity conditioning regimen consisted of oral Busulfan, rabbit anti-thymocyte globulin, and Fludarabin.
  
  
  RESULTS
  Median age was 50 years (range, 18-64 years). The incidences of acute and chronic graft-vs.-host disease were 43% and 81%, respectively. The probability of nonrelapse mortality at 1 and 5 years was 15% and 25%, respectively. Nonrelapse mortality was adversely associated with acute graft-vs.-host disease (hazard ratio = 6; p = 0.0002). Of the 52 patients with measurable disease, 37 (71%) achieved a response. Relapse/progression occurred at a median of 11 months (range 1-52 months) in 21 patients, for a cumulative incidence of 22%. The probability of overall survival and progression-free survival at 5 years were 60% and 54%, respectively. Overall survival and progression-free survival were favorably influenced by having had previous autologous stem cell transplantation and a low CD34(+) cell dose. Overall survival, progression-free survival, and nonrelapse mortality improved over time in this cohort of patients.
  
  
  CONCLUSIONS
  These results are encouraging for populations different in term of age, diagnosis, and disease status.
authors.affiliation: Unite de Transplantation et de Therapie Cellulaire, Institut Paoli Calmettes, 232 Boulevard Sainte Marguerite, Marseille, France. blaised@marseille.fnclcc.fr
authors.forename: Didier
authors.initials: D
authors.lastname: Blaise
authors.forename: Laure
authors.initials: L
authors.lastname: Farnault
authors.forename: Catherine
authors.initials: C
authors.lastname: Faucher
authors.forename: Nicholas
authors.initials: N
authors.lastname: Marchetti
authors.forename: Sabine
authors.initials: S
authors.lastname: Fürst
authors.forename: Jean
authors.initials: J
authors.lastname: El Cheikh
authors.forename: Patrick
authors.initials: P
authors.lastname: Ladaique
authors.forename: Norbert
authors.initials: N
authors.lastname: Vey
authors.forename: Reda
authors.initials: R
authors.lastname: Bouabdallah
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Stoppa
authors.forename: Claude
authors.initials: C
authors.lastname: Lemarie
authors.forename: Boris
authors.initials: B
authors.lastname: Calmels
authors.forename: Thomas
authors.initials: T
authors.lastname: Prebet
authors.forename: Luca
authors.initials: L
authors.lastname: Castagna
authors.forename: Christian
authors.initials: C
authors.lastname: Chabannon
authors.forename: Mohamad
authors.initials: M
authors.lastname: Mohty
authors.forename: Benjamin
authors.initials: B
authors.lastname: Esterni
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000961:Antilymphocyte Serum; D002066:Busulfan / Q000008:administration & dosage*; D005260:Female; D006086:Graft vs Host Disease / Q000401:mortality; D019337:Hematologic Neoplasms / Q000401:mortality / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019172:Transplantation Conditioning; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; C512542:thymoglobulin; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine